Alnylam Pharmaceuticals Inc (ALNY)
240.83
+0.64
(+0.27%)
USD |
NASDAQ |
Jun 26, 10:21
Alnylam Pharmaceuticals SG&A Expense (Annual): 795.65M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 795.65M |
| December 31, 2022 | 770.66M |
| December 31, 2021 | 620.64M |
| December 31, 2020 | 588.42M |
| December 31, 2019 | 479.00M |
| December 31, 2018 | 382.36M |
| December 31, 2017 | 199.36M |
| December 31, 2016 | 89.35M |
| December 31, 2015 | 60.61M |
| December 31, 2014 | 44.53M |
| December 31, 2013 | 27.15M |
| Date | Value |
|---|---|
| December 31, 2012 | 43.72M |
| December 31, 2011 | 38.28M |
| December 31, 2010 | 37.40M |
| December 31, 2009 | 39.91M |
| December 31, 2008 | 27.12M |
| December 31, 2007 | 23.39M |
| December 31, 2006 | 16.63M |
| December 31, 2005 | 13.87M |
| December 31, 2004 | 11.94M |
| December 31, 2003 | 7.527M |
| December 31, 2002 | 0.88M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
479.00M
Minimum
2019
795.65M
Maximum
2023
650.87M
Average
620.64M
Median
2021
SG&A Expense (Annual) Benchmarks
| BridgeBio Pharma Inc | 150.59M |
| Pfizer Inc | 14.77B |
| Biomarin Pharmaceutical Inc | 937.30M |
| Merck & Co Inc | 10.50B |
| Arvinas Inc | 100.30M |